INS and type 2 diabetes mellitus: The efficacy and safety of insulin icodec (herein simply referred to as ‘icodec’), a once-weekly basal insulin analogue, have been evaluated vs once-daily basal insulin comparators in five Phase 3a trials in adults with type 2 diabetes (ONWARDS 1–5 [ClinicalTrials.gov registration nos NCT04460885, NCT04770532, NCT04795531, NCT04880850 and NCT04760626, respectively]) [4–10].